NA-Semax & NA-Selank

Wellness

Also known as: N-Acetyl Semax Amidate, N-Acetyl Selank Amidate, NA-Semax Amidate, NA-Selank Amidate

Unproven

What is NA-Semax & NA-Selank?

Chemically modified analogs of Semax and Selank — the two Russian-developed nootropic/anxiolytic peptides that already have their own registered-drug history. NA-Semax and NA-Selank add an acetyl group to the N-terminus and an amide group to the C-terminus of each parent peptide. These modifications are not made or sold by the Russian pharmaceutical companies behind the original nasal-spray drugs; they are Western research-chemical/biohacking-market products built on the theory that end-capping resists enzymatic degradation. Vendors market them as stronger, longer-lasting, lower-dose versions of Semax and Selank, but there is essentially no independent published pharmacokinetic or clinical data on the modified molecules themselves — the claims trace back to seller copy and general peptide-chemistry reasoning, not head-to-head studies.

How it works

NA-Semax and NA-Selank retain the same core amino acid sequences as their parent peptides — Semax's ACTH(4-10)-derived fragment and Selank's tuftsin-related heptapeptide — so in theory they act on the same targets: BDNF/NGF upregulation and dopaminergic/serotonergic modulation for the Semax backbone, and GABA-A/serotonin modulation plus enkephalin stabilization for the Selank backbone. What's added is an acetyl cap on the N-terminus and an amide group replacing the free C-terminal carboxylic acid. Both modifications are well-known peptide-stabilization tactics in medicinal chemistry generally — they block aminopeptidase and carboxypeptidase enzymes from chewing in from either end of the chain, which can slow degradation and extend plasma half-life for many peptides. The leap sellers make is assuming this general principle produces a meaningfully longer-acting, more potent, lower-dose version of Semax and Selank specifically. That assumption has not been confirmed by any published pharmacokinetic study directly comparing the acetylated/amidated analogs to the parent compounds in animals or humans.

What marketers claim

▸dramatically more potent than regular Semax or Selank (vendors cite figures ranging loosely up to 10x or more)
▸much longer duration of action — some listings claim a half-life several times that of the parent peptide
▸allows a lower effective dose than plain Semax or Selank
▸more stable at room temperature, reducing or eliminating the need for refrigeration
▸superior blood-brain-barrier penetration compared to the unmodified peptide
▸a strictly upgraded, next-generation version of the original Russian peptides

What evidence supports

✓the underlying chemistry principle — that N-terminal acetylation and C-terminal amidation can slow exopeptidase degradation — is well established in peptide science generally and is used in a number of approved drugs, so the mechanism is chemically plausible
✓the parent compounds have real (if regionally limited) backing: Semax and Selank are registered nasal-spray drugs in Russia with decades of published Russian-language clinical use for cognitive/stroke recovery and anxiolytic indications, respectively — but that evidence was generated on the unmodified peptides, not on these analogs
✓no independently published pharmacokinetic study has compared NA-Semax or NA-Selank against plain Semax or Selank in humans or animals — the "longer half-life" and "more potent" figures circulated by sellers are inconsistent from vendor to vendor, which is itself a sign they are not derived from a shared dataset
✓the original Russian manufacturers of Semax and Selank do not produce, register, or endorse the acetylated/amidated variants; NA-Semax and NA-Selank exist exclusively as gray-market research-chemical products, not as an evolution of the pharmaceutical product

Best for

peptide chemistry enthusiasts specifically curious about acetylation/amidation modification techniques, who understand this is unstudied gray-market territory rather than an upgraded medicine

What to expect

Realistic timeline based on available research. Individual results vary.

Vendor claims (immediate, per marketing copy)

Seller pages assert onset and effects comparable to or faster than plain Semax/Selank, with a longer overall duration of action — but these timelines are not sourced to any published study.

Actual published evidence to date

No peer-reviewed pharmacokinetic or clinical timeline exists for NA-Semax or NA-Selank specifically. All duration and potency figures in circulation originate from vendor product pages and informal biohacking forum discussion, not research.

What would be needed to change this

A head-to-head pharmacokinetic study comparing plasma/CNS levels of the acetylated-amidated analog against the parent peptide, followed by controlled efficacy comparisons, would be required before any of the current potency or duration claims could be considered established.

Safety notes & concerns

Full safety guide →

⚠zero independent human pharmacokinetic or efficacy data exists for either modified analog specifically — everything cited by sellers is either theoretical chemistry reasoning or unattributed vendor claims
⚠even the parent peptides carry meaningfully weaker evidence than Western-approved drugs (small trials, mostly Russian-language literature); the NA- variants sit one further step removed from that already-limited base
⚠dosing guidance for NA-Semax and NA-Selank is not derived from any study — it is extrapolated by sellers from the parent peptide's dosing, adjusted downward on the unverified assumption of higher potency
⚠no data exists on whether acetylation/amidation changes receptor binding selectivity, introduces new metabolites, or alters the immune/allergenic profile compared to the parent peptide
⚠sourced exclusively through unregulated research-chemical vendors with no GMP oversight, third-party purity testing is inconsistent, and mislabeled or degraded product is a realistic risk
⚠sold and labeled "for research purposes only, not for human consumption" while being marketed and used as a self-administered nootropic/anxiolytic — a legal and safety gray area
⚠marketing claims of improved stability and no need for refrigeration have not been independently verified for these specific compounds

Pairs well with

not established — no dosing or interaction data exists for these analogs, so pairing recommendations from sellers are speculative

Use caution with

anyone expecting the same evidence base as the parent Semax/Selank — the modification itself has not been separately studiedcurrent psychiatric medication without physician guidance (same caution that applies to plain Selank/Semax, compounded by the total lack of data on the modified form)pregnancy or breastfeedingtreating this as a substitute for the actual registered drug products where cost, legality, or access make that a realistic option

Frequently asked questions

Is NA-Semax actually stronger or longer-lasting than regular Semax?

That is the core marketing claim, but it has not been demonstrated in any published study. The chemistry argument — that capping both ends of the peptide slows enzymatic breakdown — is plausible in general terms, but no independent pharmacokinetic comparison between NA-Semax and plain Semax has been published. The specific potency and half-life multipliers seen on vendor sites vary from seller to seller, which suggests they are estimates or marketing figures rather than measured data.

Is there any real evidence for the acetylated/amidated version specifically?

No independent clinical or pharmacokinetic evidence exists for NA-Semax or NA-Selank as distinct compounds. What evidence does exist applies to the parent peptides — Semax and Selank's Russian clinical and registration data — and that data does not automatically transfer to a chemically modified analog. Treat any specific claim about the 'NA-' versions as unverified until an actual comparative study is published.

Do the original Russian companies make NA-Semax and NA-Selank?

No. The pharmaceutical companies that manufacture and hold registration for Semax and Selank as approved nasal-spray drugs in Russia produce only the unmodified peptides. NA-Semax and NA-Selank are Western research-chemical products developed and sold independently of those manufacturers, with no formal affiliation or endorsement.

Why do sellers claim these versions need less frequent dosing?

The reasoning is that acetylation and amidation slow the enzymatic breakdown that normally clears Semax and Selank quickly from the body, so a smaller or less frequent dose could theoretically achieve a similar effect. This is a reasonable hypothesis based on general peptide chemistry, but it hasn't been tested for these specific molecules, so any dosing schedule offered by a vendor is an estimate, not a study-derived recommendation.

Should I just use regular Semax or Selank instead?

If you're going to use one of these peptides at all, the parent compounds have a meaningfully larger (though still Russia-centric and limited-by-Western-standards) evidence base than the acetylated/amidated analogs, which currently have none. Choosing the unmodified version means relying on the more-studied — if still imperfect — option rather than an unstudied further modification.